美国芝加哥当地时间6月2日-6日即将迎来在2023年度的全球规模最大的肿瘤领域学术交流盛会——第59届美国临床肿瘤学会(ASCO)会议。届时,全球顶尖肿瘤学专家将汇聚一堂,共同分享、探讨国际最前沿的临床肿瘤学研究成果和治疗技术。
目前,ASCO官网已公布了本次会议的日程和摘要题目。本期【血液肿瘤资讯】整理了2023 ASCO年会全体大会及口头报告(Oral Abstract Session)专场的恶性血液肿瘤重磅研究,与读者分享。
全体大会
专场时间:2023年6月5日,星期一,上午2:00 – 上午5:00(以下时间均为中国时间)
专场主席:Katia Khoury,Kevin Kalinsky
摘要号:LBA4
SWOG S1826:一项纳武利尤单抗(N) - AVD vs 维布妥昔单抗(BV)- AVD治疗晚期(AS)经典霍奇金淋巴瘤(HL)的随机研究
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).
讲者:Alex Francisco Herrera, MD | City of Hope National Medical Center
口头报告专场:恶性血液肿瘤——白血病、骨髓增生异常综合征和同种异体移植
专场时间:2023年6月3日,星期六,上午02:00 – 上午05:00
专场主席:Andrew Artz | City of Hope National Medical Center;Vanessa Kennedy | University of California, San Francisco
摘要号:7000
obecabtagene autoleucel [obe-cel,AUTO1, 一种具有较快解离速度的嵌合抗原受体(CAR)]治疗复发/难治性(R/R)成人急性B淋巴细胞白血病(B - ALL)的疗效及安全性:关键FELIX研究的主要结果
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
讲者:Claire Roddie, PhD, FRCPath, MBChB, MRCP, BSc | University College London
摘要号:7001
作为R/R B - ALL的美国食品药品监督管理局(FDA)获批疗法,brexucabtagene autoleucel治疗R / R B - ALL成人患者的结局
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.
讲者:Gregory Roloff, MD | University of Chicago
摘要号:7002
经酪氨酸激酶抑制剂(TKI)制备的CD5 CAR - T细胞治疗R / R 急性T淋巴细胞白血病(T - ALL)患者的抗肿瘤活性增强
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.
讲者:LaQuisa C Hill, MD | Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital
摘要号:7003
COMMANDS试验的疗效及安全性结果:一项评估luspaterceept vs重组人红细胞生成素(ESA)治疗伴低风险骨髓增生异常综合征(LR - MDS)的促红细胞生成剂初次输血依赖(TD)患者的3期研究
Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)‑naive transfusion-dependent (TD) patients (pts) with lower‑risk myelodysplastic syndromes (LR-MDS).
讲者:Guillermo Garcia-Manero, MD | Department of Leukemia, University of Texas M.D. Anderson Cancer Center
摘要号:7004
IMerge:imetelstat治疗伴低风险骨髓增生异常综合征(LR - MDS)的严重输血依赖(TD)非del(5q)且对重组人红细胞生成素(ESA)复发/难治(R / R)患者的一项随机、双盲、安慰剂对照的3期研究结果
IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
讲者:Amer Methqal Zeidan, MBBS | Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University
摘要号:7005
CD123 NK细胞接合物SAR443579治疗R / R急性髓性白血病(AML)、急性B淋巴细胞白血病或高危骨髓异常增生的首次人体研究
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
讲者:Anthony Selwyn Stein, MD | City of Hope National Medical Center
摘要号:7006
Alliance A041703:inotuzumab ozogamicin联合blinatumumab的去化疗方案治疗新诊断、Ph阴性、CD22阳性老年急性B淋巴细胞白血病患者
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.
讲者:Matthew Joseph Wieduwilt, MD, PhD | Atrium Health Wake Forest Baptist Comprehensive Cancer Center
摘要号:7007
剂量调整的EPOCH联合inotuzumab ozogamicin (InO)治疗R / R B淋巴母细胞白血病/淋巴瘤(B - ALL)成人患者的I期临床试验
A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).
讲者:Noam Edward Kopmar, MD | University of Washington/Fred Hutchinson Cancer Center
摘要号:7008
AYA ALL的特殊癌症治疗和生存:一项美国多州分析
Specialty cancer care and survival in AYA ALL: A U.S. multi-state analysis.
讲者:Lori S. Muffly, MD, MS | Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine
口头报告专场:恶性血液肿瘤——恶性浆细胞疾病
专场时间:2023年6月4日,星期日,上午02:15 – 上午5:15
专场主席:Amandeep Godara | Huntsman Cancer Institute;Luciano Costa | University of Alabama at Birmingham
摘要号:8000
卡非佐米、来那度胺和地塞米松(KRd) vs. elotuzumab和KRd治疗符合移植条件的新诊断多发性骨髓瘤(MM)患者:一项开放标签、随机、3期研究的诱导后应答和MRD结果
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.
讲者:Stefan Knop, MD | Wuerzburg University Medical Center
摘要号:8001
卡非佐米、泊马度胺和地塞米松(KPd)维持治疗高危骨髓瘤患者:一项2期研究的安全性导入期
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.
讲者:Ajay K. Nooka, MBBS | Winship Cancer Center of Emory University
摘要号:8002
Teclistamab (tec)和talquetamab (tal)(同时靶向于BCMA和GPRC5D)治疗复发/难治性多发性骨髓瘤(RRMM)患者的RedirecTT-1研究的首次结果
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
讲者:Yael C Cohen, MD | Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University
摘要号:8003
Talquetamab(tal)联合达雷妥尤单抗(dara)治疗复发/难治性多发性骨髓瘤(RRMM)患者: TRIMM-2研究的最新结果
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.
讲者:Bhagirathbhai R. Dholaria, MBBS | Vanderbilt University Medical Cente
摘要号:8004
PHE885(一种T-Charge制备的靶向BCMA的CAR-T细胞疗法)治疗RRMM患者的最新I期研究结果
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
讲者:Adam Samuel Sperling, MD, PhD | Dana-Farber Cancer Institute
摘要号:8005
BCMA/CD19双靶向fast CAR-T GC012F治疗复发/难治性多发性骨髓瘤(RRMM)患者的开放标签I期研究的更新结果
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
讲者:杜鹃教授 | 上海长征医院
摘要号:8006
LINKER-MM1研究:Linvoseltamab(REGN5458)治疗复发/难治性多发性骨髓瘤(RRMM)患者
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
讲者:Hans C. Lee, MD | The University of Texas MD Anderson Cancer Center
摘要号:8007
评估belantamab mafodotin(belamaf)单药 vs 泊马度胺联合低剂量地塞米松(Pd)治疗复发/难治性多发性骨髓瘤(RRMM)患者的疗效与安全性的一项3期、开放标签、随机研究:DREAMM‑3
A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM‑3.
讲者:Katja Weisel, MD | University Medical Center of Hamburg-Eppendorf
摘要号:8008
Elranatamab治疗既往经B细胞成熟抗原(BCMA)靶向治疗的复发/难治性多发性骨髓瘤(RRMM)患者的疗效和安全性:来自MagnetisMM研究的汇总分析
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
讲者:Ajay K. Nooka, MBBS | Winship Cancer Institute, Emory University Hospital
口头报告专场:恶性血液肿瘤——淋巴瘤和慢性淋巴细胞白血病
专场时间:2023年6月6日,星期二,下午10:45 – 上午13:45
专场主席:Boyu Hu | Hunstman Cancer Institute at the University of Uta;Jakub Svoboda | University of Pennsylvania
摘要号:7500
一项IVO vs IO治疗既往未接受治疗的老年慢性淋巴细胞白血病(CLL)患者的3期研究结果以及COVID-19的影响(Alliance)
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
讲者:Jennifer Ann Woyach, MD | The Ohio State University Comprehensive Cancer Center
摘要号:7501
Lisocabtagene maraleucel(liso - cell)治疗R/R慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL): TRANSCEND CLL 004研究的初步分析
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.
讲者:Tanya Siddiqi, MD | City of Hope National Medical Center
摘要号:7502
MOLTO研究的结果:评估维奈克拉、阿替利珠单抗联合obinutuzumab治疗Richter综合征疗效的一项多中心、开放标签、II期临床试验
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.
讲者:Anna Maria Frustaci, MD | Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda
摘要号:7503
Golidocitinib治疗难治性或复发性外周T细胞淋巴瘤:国际关键性研究结果的主要分析(JACKPOT8)
Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).
讲者:中国广东,中山大学附属肿瘤防治中心,蔡清清教授
摘要号:7504
CHOP联合抗CCR4抗体mogamulizumab治疗老年CCR4阳性成人T细胞白血病/淋巴瘤患者的2期临床试验
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.
讲者:Ilseung Choi | Department of Hematology and Cell therapy, National Hospital Organization Kyushu Cancer Center
摘要号:7505
观察 vs 放疗用于对于标准免疫化疗完全缓解的原发性纵隔B细胞淋巴瘤患者:IELSG37随机试验
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.
讲者:Emanuele Zucca, MD | Institute of Oncology Research; Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Science, Universita’ della Svizzera italiana; International Extranodal Lymphoma Study Group (IELSG)
摘要号:7506
Epcoritamab 联合R2方案治疗高风险滤泡性淋巴瘤(FL)的应答情况
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
讲者:Reid Merryman, MD | Dana-Farber Cancer Institute
摘要号:7507
Brexucabtagene autoleucel(brexu - cel)治疗R/R套细胞淋巴瘤(MCL)的真实世界结局:一项CIBMTR亚组分析(不同既往治疗情况下)
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
讲者:Swetha Kambhampati, MD | City of Hope National Medical Center
摘要号:7508
利妥昔单抗维持治疗年轻套细胞淋巴瘤(MCL)患者的长期随访(包含于LYMA试验中):一项LYSA研究
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.
讲者:Steven Le Gouill, MD PhD | Institut Curie
本文依照报告日期和出场排序整理,如有错误或遗漏,敬请留言指正。
资料来源:
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions
排版编辑:Luna